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Contraception and sexually transmitted infections: risks and 
beneﬁ ts, hypotheses and evidence
Women bear most of the worldwide burden of sexually 
transmitted infections (STIs) and their resultant 
morbidity and mortality.1 However, STIs are only 
one adverse health threat borne disproportionately 
by women, who also face important risks related to 
reproductive health, violence and trauma, economic 
instability, and other areas. Interventions that aim to 
mitigate these risks can have substantial public health 
success, but occasionally interventions inadvertently 
generate new risks as well.
Hormonal forms of contraception, including 
oral contraceptive pills, progestin-only injectables 
such as depo-medroxyprogesterone acetate (DMPA), 
and hormone-containing technologies (implants, intra-
uterine devices, patches, and rings) are used by more 
than 150 million women worldwide, and worldwide 
implementation of safe and eﬀ ective contraception 
has had substantial public health eﬀ ect on prevention 
of unintended pregnancy and maternal morbidity.2 
Contraceptives, though, are not without risk, and some 
methods have been associated with increased likelihood 
of complications, such as thromboembolic disease.3 
Still, when weighed against the substantial health 
and economic beneﬁ ts aﬀ orded by prevention of 
unintended pregnancy, the public health balance 
favours widespread access to a diverse assortment of 
safe and eﬀ ective contraceptive methods as a public 
health imperative.
In The Lancet Global Health, Grabowski and colleagues4 
report that women consistently using DMPA were 
at nearly double the risk of acquiring herpes simplex 
virus type 2 (HSV2) compared with those using no 
contraception; in a sensitivity analysis limited to those 
whose main partner had HSV2, the risk increased by six 
times. HSV2, the cause of genital herpes, is prevalent 
in populations worldwide, including in Africa, and is 
a common cause of morbidity related to genital ulcer 
disease and of rare serious morbidity in infants with 
neonatal infection; it is also an important risk factor for 
HIV acquisition in adults.5 The results from Grabowski 
and colleagues build on a large and contentious body of 
evidence suggesting that DMPA might increase HIV risk,6 
and a smaller number of studies exploring associations 
of contraceptives with other STIs. Although we have 
contributed to this discussion with observational data 
showing increased HIV risk associated with DMPA,7 
we acknowledge that results across studies have been 
inconsistent and the answer is still unclear.
Authors of meta-analyses8,9 have noted increased 
risk estimates for an association between DMPA 
and HIV association, but those results are only as 
strong as the observational data from which they 
derive, and important criticisms of the observational 
scientiﬁ c literature in this discipline have been raised,10 
including small sample sizes, reliance on self-reported 
contraceptive exposures, infrequent ascertainment of 
HIV and other STI outcomes, and inconsistent methods 
and ﬁ ndings, persisting even into recent studies.11 
Notably, the Rakai Program previously identiﬁ ed no 
increased HIV risk related to DMPA in the population 
from which the present HSV2 risk was noted,12 and the 
only other cohort to explore DMPA’s eﬀ ects on HIV and 
HSV2 came to the opposite conclusion—increased HIV 
risk with no increase in HSV2 acquisition.13,14
We and others have argued that rigorous studies, 
with suﬃ  cient samples sizes and robust measurement 
of contraceptive exposures, infection outcomes, and 
behavioural confounders, including the potential 
for a randomised trial,15 are essential now to address 
outstanding questions related to contraceptives and 
HIV and STIs. The HSV2 results from Grabowski and 
colleagues’ study rest on just nine incident HSV2 
cases of those using DMPA and infrequent annual 
assessments of contraceptive exposure, HSV2 outcome, 
and confounding factors, so we therefore agree 
with Grabowski and colleagues that the results are 
hypothesis-generating but not deﬁ nitive evidence. For 
such a topic that intersects at two priority areas of global 
health—STIs and reproductive health—to have more 
hypotheses than clear evidence is frustrating—and sends 
a message to women that is complex and confusing.
Importantly, potential infectious risks (HSV2, other 
STIs, and HIV) that might increase with use of some 
contraceptives should be weighed carefully because 
infections are not the only risks. Some have called for 
removal of DMPA from settings with high HIV and STI 
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risks, but in Rakai, like in many other parts of Africa, 
DMPA is the dominant contraceptive chosen by women, 
showing desire for its eﬀ ectiveness, ease of use, and 
ability to be used discretely,  and its ease of delivery 
by health systems. Eﬀ orts to expand contraceptive 
method options by introduction of long-acting eﬀ ective 
methods such as implants and intrauterine devices in 
settings like Rakai are sorely needed, but acceptability, 
deliverability, and STI and HIV risks of new contraceptive 
methods are outstanding issues, leaving open the 
potential for risks that are as yet unanticipated. 
Ultimately, attention to inter-relations between contra-
ceptive options and STI and HIV outcomes is a strong 
reminder of the priority for integrated sexual and 
reproductive health research, grounded in evidence as it 
emerges and weighing risks and beneﬁ ts that are crucial 
to health-care programming and delivery.
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